Semaglutide and tirzepatide are both highly effective for weight loss, but tirzepatide generally produces greater reductions in body weight, with average losses of up to 22.5% versus 14.9% for semaglutide in clinical trials. In Canada, both medications are available by prescription, though tirzepatide is newer and may be less accessible depending on provincial coverage. This article compares the two GLP-1 receptor agonists head-to-head so you can decide which is better for your goals.
How Semaglutide and Tirzepatide Work for Weight Loss
Semaglutide is a GLP-1 receptor agonist. It mimics the hormone glucagon-like peptide-1, which reduces appetite, slows gastric emptying, and increases insulin secretion after meals. Tirzepatide is a dual agonist, activating both GLP-1 and GIP receptors. GIP enhances insulin sensitivity and may further suppress appetite. This dual action is why tirzepatide often outperforms semaglutide in head-to-head studies.
Both drugs are injected weekly. Semaglutide is sold as Ozempic (for diabetes) and Wegovy (for weight loss). Tirzepatide is sold as Mounjaro (for diabetes) and Zepbound (for weight loss). In Canada, Wegovy and Mounjaro are approved for chronic weight management, while Ozempic is often prescribed off-label for weight loss.
Clinical Trial Results: Head-to-Head Weight Loss Data
The SURMOUNT-1 trial tested tirzepatide in people without diabetes. At the highest dose (15 mg weekly), participants lost an average of 22.5% of their body weight after 72 weeks. The STEP 1 trial for semaglutide (2.4 mg weekly) showed an average loss of 14.9% over 68 weeks. A direct comparison study, SURMOUNT-5, found tirzepatide led to significantly greater weight loss than semaglutide: 20.2% versus 13.7% at 72 weeks.
For a 100 kg person, that translates to about 20 kg lost with tirzepatide versus 14 kg with semaglutide. However, individual results vary. Some people respond better to one drug than the other due to genetics, side effects, or adherence.
Side Effects and Tolerability in Canadian Patients
Both medications share similar gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and fade over time. Tirzepatide may cause slightly more nausea at higher doses, but this often resolves with slow dose titration. Semaglutide has a longer track record, with more long-term safety data. Tirzepatide is newer, but its safety profile appears similar.
Rare but serious risks include pancreatitis, gallbladder disease, and medullary thyroid cancer (seen in rodents, not confirmed in humans). Both drugs should be avoided in pregnancy and in people with a personal or family history of medullary thyroid carcinoma or MEN2. In Canada, doctors must screen for these before prescribing.
Cost and Insurance Coverage in Canada
Cost is a major factor for many Canadians. Wegovy (semaglutide 2.4 mg) costs about $400 to $500 per month without insurance. Zepbound (tirzepatide) is not yet marketed in Canada, but Mounjaro (tirzepatide) is available for diabetes and often prescribed off-label for weight loss. Mounjaro costs roughly $350 to $450 per month. Private insurance may cover these drugs if prescribed for diabetes, but coverage for weight loss alone is inconsistent. Public drug plans vary by province: Quebec, Ontario, and British Columbia have limited coverage for semaglutide in specific cases, while tirzepatide coverage is rare.
If cost is a barrier, some Canadians turn to compounded semaglutide or tirzepatide from regulated pharmacies. However, Health Canada warns against unregulated online sellers. Always verify the pharmacy is licensed.
Dosing Protocols: How to Start and Titrate
Semaglutide for weight loss starts at 0.25 mg weekly for four weeks, then increases every four weeks to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg. Tirzepatide starts at 2.5 mg weekly and increases by 2.5 mg every four weeks to a maximum of 15 mg. Slower titration reduces nausea. Many doctors in Canada pause at an effective dose rather than pushing to the maximum.
Both drugs are injected subcutaneously in the abdomen, thigh, or upper arm. They can be taken with or without food. Missed doses should be taken within 5 days; otherwise, skip and resume the regular schedule.
Which One Should You Choose? A Practical Comparison
If maximum weight loss is your priority and cost is not a barrier, tirzepatide is likely the better choice based on clinical data. If you have type 2 diabetes, both drugs improve glycemic control, but tirzepatide may offer greater A1c reduction. If you prefer a medication with longer safety data and broader insurance coverage in Canada, semaglutide may be more accessible.
Some patients switch from semaglutide to tirzepatide after plateauing. Others find semaglutide sufficient and better tolerated. Discuss with your doctor, especially if you have other conditions like fatty liver or cardiovascular risk. For more on how GLP-1 drugs affect other behaviors, see our article on semaglutide and alcohol cravings research in Quebec.
Availability and Prescribing Rules in Canada
Both semaglutide and tirzepatide require a prescription from a Canadian physician or nurse practitioner. Telehealth services like Felix, Livewell, and Maple can prescribe after an online assessment. However, not all provinces allow telehealth prescribing for weight loss. In Quebec, for example, a video consultation is mandatory. Pharmacies may have shortages, especially for higher doses of tirzepatide. Check with your local pharmacy about stock before starting.
If you are considering other peptides for weight loss, compare options like MOTS-c dosage for fat loss in Canada or AOD-9604 for fat loss in Quebec. These are not as potent as GLP-1 drugs but may be used off-label by some.
Long-Term Maintenance and Weight Regain
Weight regain after stopping either drug is common. Studies show that most people regain about two-thirds of lost weight within a year of discontinuation. Therefore, these medications are intended for long-term use. Maintenance doses may be lower than the maximum. Some patients taper to a lower dose or switch to a cheaper option like oral semaglutide (Rybelsus) if available.
Lifestyle changes remain essential. A reduced-calorie diet and regular physical activity improve results and help maintain muscle mass. Resistance training is particularly important because rapid weight loss can include lean tissue loss. For muscle recovery support, some users combine peptides like BPC-157 or TB-500, but these are not approved for weight loss. Learn more about BPC 157 vs TB500 dosage for muscle recovery in Canada.
Frequently Asked Questions
Is tirzepatide approved for weight loss in Canada?
Yes, tirzepatide is approved as Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition. However, Zepbound is not yet marketed in Canada; Mounjaro (same drug) is available for type 2 diabetes and often used off-label for weight loss.
Can I take semaglutide and tirzepatide together?
No, combining GLP-1 receptor agonists is not recommended and increases the risk of severe gastrointestinal side effects. Choose one and titrate appropriately.
Which is cheaper in Canada: semaglutide or tirzepatide?
Semaglutide (Wegovy) is generally cheaper than tirzepatide (Mounjaro) at retail prices, but insurance coverage varies. Compounded versions may be less expensive but carry quality risks.
How fast do you lose weight on tirzepatide vs semaglutide?
Most weight loss occurs in the first 6 to 9 months. Tirzepatide users may see faster initial loss due to stronger appetite suppression, but individual responses vary.
Final Verdict: Best GLP-1 for Weight Loss in Canada
For most people, tirzepatide offers superior weight loss efficacy, with clinical trials showing up to 22.5% body weight reduction. Semaglutide remains a strong option with more long-term data and wider insurance coverage. Your choice should depend on cost, side effect tolerance, and availability in your province. Always consult a healthcare provider before starting any GLP-1 medication. For more on anti-aging and metabolic peptides, read our guide on MOTS-c dosage for anti-aging in Canada.
Share This Article